DF/HCC Kidney Cancer SPORE

DF/HCC 肾癌孢子

• 批准号: 8931861
• 负责人: WILLIAM G. KAELIN
• 金额: $ 218.5万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-18 至 2020-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8931861
• 关键词: Address; Angiogenesis Inhibitors; Basic Science; Biological Markers; Biometry; Boston; Cancer Biology; Cancer Center; Center Core Grants; Chromatin; Clear Cell; Clinical; Clinical Data; Clinical Research; Communities; Computational Biology; Critical Pathways; Dana-Farber Cancer Institute; Development; Device or Instrument Development; Evaluation; Funding; Future; General Hospitals; Genetic Markers; Genomics; Goals; Grant; Health; Hospitals; Immune; Immunotherapy; Incentives; Institutes; Institution; Israel; Knowledge; Laboratory Scientists; Massachusetts; Medical center; Mentors; Mission; Molecular; Monitor; Mutation; New Agents; Oncogenic; Outcome; Pathology; Pathway interactions; Patients; Pediatric Hospitals; Physicians; Pre-Clinical Model; Prognostic Marker; Public Health Schools; Regulator Genes; Renal carcinoma; Reporting; Research; Research Infrastructure; Research Personnel; Resistance; Scientist; Seasons; Secondary to; Specialized Program of Research Excellence; Stream; Talents; Technology; Testing; The Cancer Genome Atlas; Therapeutic Index; Time; Tissues; Toxic effect; Translational Research; Treatment outcome; Woman; anticancer research; base; career; career development; clinical investigation; drug development; effective therapy; genetic analysis; human FRAP1 protein; improved; knowledge base; medical schools; member; novel; outcome forecast; patient population; programs; resistance mechanism; response; success; therapy development; tool

DESCRIPTION (provided by applicant): This application represents a resubmission of a competing renewal application for a Specialized Program of Research Excellence (SPORE) in Kidney Cancer from the Kidney Cancer Program of Dana-Farber/Harvard Cancer Center (DF/HCC). The DF/HCC Kidney Cancer SPORE has been funded for two cycles since 2003. DF/HCC is comprised of the following institutions: Beth Israel-Deaconess Medical Center (BIDMC); Dana- Farber Cancer Institute (DFCI); Harvard Medical School; Harvard School of Public Health; Brigham and Women's Hospital; Massachusetts General Hospital (MGH); and Children's Hospital of Boston. In addition to the institutions in the DF/HCC, the Whitehead Institute at Massachusetts Institute of Technology and Georgetown-Lombardi Cancer Center (GLCC) are collaborating institutions in this grant. The DF/HCC Kidney Cancer SPORE has its administrative base at the BIDMC. Dr. David McDermott, who has led the DF/HCC Kidney Cancer Program and SPORE since 2012 is joined as SPORE Director by Dr. William Kaelin, a laboratory scientist at DFCI and Associate Director for Basic Science in the DF/HCC. Drs. McDermott and Kaelin report directly to Dr. Edward Benz, Director of DF/HCC and President of DFCI. The DF/HCC Kidney Cancer SPORE has a broad and deep talent base and there is extensive institutional commitment. We take advantage of a large patient population and cutting edge technologies that are available to us as part of DF/HCC. We propose 4 Projects which address critical problems in kidney cancer and have translational components. They focus on identifying effective strategies for targeting: HIF2α, the dominant oncogenic driver of clear-cell RCC (Project 1), angiogenesis inhibitor resistance mechanisms, which undermine the most commonly applied therapies (Project 2) and improving the therapeutic index of agents targeting the mTOR (Project 3) and immune checkpoint pathways (Project 4). The projects are supported by three Cores - an Administrative Core, a Biostatistics and Computational Biology Core, and a Tissue Acquisition, Pathology and Clinical Data Core. We also have a highly successful Career Development Program that selects talented physician scientists and mentors them to independence as well as a Developmental Projects Program that generates new ideas for the SPORE in the future. The existence of the SPORE has provided opportunities and incentives to extend basic science and clinical research ideas into the translational realm and facilitated the entry of young, as well as some seasoned, investigators into the kidney cancer field where they have made major contributions.

描述(由申请者提供)：本申请是Dana-Farber/哈佛癌症中心(DF/HCC)肾癌项目的卓越研究专科项目(Spoor)的重新提交的竞争性续签申请。自2003年以来，DF/HCC肾癌孢子已经获得了两个周期的资助。DF/HCC由以下机构组成：贝丝以色列-女执事医疗中心(BIDMC)、达纳-法伯癌症研究所(DFCI)、哈佛医学院、哈佛公共卫生学院、布里格姆妇女医院、马萨诸塞州总医院(MGH)和波士顿儿童医院。除了DF/HCC的机构外，麻省理工学院的怀特黑德研究所和乔治敦-隆巴迪癌症中心(GLCC)也是这笔赠款的合作机构。DF/HCC肾癌孢子在BIDMC有其管理基础。大卫·麦克德莫特博士自2012年以来一直领导DF/HCC肾癌项目和孢子，DFCI的实验室科学家兼DF/HCC基础科学副主任William Kaelin博士也加入了孢子主任的行列。麦克德莫特博士和凯林博士直接向DF/HCC主任兼DFCI总裁Edward Benz博士汇报工作。DF/HCC肾癌孢子拥有广泛而深厚的人才基础，并有广泛的机构承诺。我们利用了大量的患者群体和尖端技术，这些技术是DF/HCC的一部分。我们提出了4个项目，这些项目解决了肾癌的关键问题，并有翻译成分。他们侧重于确定有效的靶向策略：HIF2α，透明细胞肾癌的主要致癌驱动因素(项目1)，血管生成抑制耐药机制，破坏最常用的治疗方法(项目2)，以及改善靶向mTOR和免疫检查点通路的药物的治疗指数(项目3)和免疫检查点途径(项目4)。这些项目得到了三个核心的支持--一个行政核心，一个生物统计和计算生物学核心，以及一个组织获取、病理学和临床数据核心。我们还有一个非常成功的职业发展计划，它挑选有才华的内科科学家并指导他们走向独立，以及一个开发项目计划，它为未来的孢子产生新的想法。孢子的存在提供了机会和激励，将基础科学和临床研究的想法扩展到翻译领域，并促进了年轻的和一些经验丰富的研究人员进入肾癌领域，他们在这一领域做出了重大贡献。